Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

Abstract: A non-volatile semiconductor memory device and/or a data processing system include a non-volatile memory array having a plurality of memory blocks and a write-protection control circuit that controls access to blocks of memory based on a start block address and an end block address. The write-protection control circuit may store start and end block addresses of an unlock region of the non-volatile memory array, and selectively activate a write enable signal according to the relationship between a write address and the start and end block addresses.

Abstract: An optical fiber connector can include an optical fiber interface, an identification circuit, and an electrical interface that is communicatively connected to the identification circuit. The identification circuit may be a non-volatile memory such as, for example, a read only memory, a magnetic random access memory and/or a flash-random access memory. The identification circuit may include a housing that can be releasably connected to a Light Guide Cross Connect (LGX). The identification circuit may generate an electrical signal that identifies a fiber, a fiber bundle, a fiber type, a connector type, who manufactured an optical fiber, when an optical fiber was manufactured, and/or when an optical fiber was installed. Related optical fiber distribution terminals are also discussed.